Chao Hou1,2, Hua-Jian Chu3, Xiao-Jun Dai1,2, Yin-Qiu Wu4, Zheng-Fei He5, Yan-Wei Yu1,2, Qing-Yun Lu5, Yan-Qing Liu1,2, Xiao-Chun Zhang5. 1. College of Medicine, Yangzhou University, Yangzhou 225001, Jiangsu, China. 2. The State Administration of Traditional Chinese Medicine Key Laboratory of Toxic Pathogens-Based Therapeutic Approaches of Gastric Cancer, Yangzhou University, Yangzhou 225009, Jiangsu, China. 3. Yizheng Hospital of Traditional Chinese Medicine, Yizheng 211400, Jiangsu, China. 4. Department of Immunology, Jiangsu University, Zhenjiang 212013, Jiangsu, China. 5. College of Medicine, Yangzhou Hospital of Traditional Chinese Medicine Affiliated with Nanjing University of Chinese Medicine, Yangzhou 225009, Jiangsu, China.
Abstract
OBJECTIVE: This study aimed to find new biomarkers of prognosis and metabolomic therapy for gastric carcinoma (GC) treated with chemotherapy and investigate the metabolic mechanism of the Jianpi Yangzheng Xiaozheng (JPYZXZ) decoction in the treatment of GC. METHODS: First, 36 patients with GC were randomly assigned to the treatment (chemotherapy plus JPYZXZ) and control (chemotherapy alone) groups. The clinical efficacy, side effects, and quality of life of patients in the two groups were evaluated after treatment. Then, the serum samples taken from 16 randomly selected patients (eight treatment cases and eight control cases with no evident pattern characters) and eight healthy volunteers were tested to identify the differential metabolite under the gas chromatography-time-of-fight mass spectrometry platform. The relevant metabolic pathways of differential substances were analyzed using multidimensional statistical analysis. RESULTS: JPYZXZ combined with chemotherapy resulted in a lower risk of leucopenia, thrombocytopenia, and gastrointestinal reaction (P < 0.05). Additionally, patients in the treatment group showed a higher Karnofsky (KPS) scale (P < 0.05). Compared with healthy persons, patients with GC were found to have 26 significant differential metabolites after chemotherapy; these metabolites are mainly involved in 12 metabolic pathways, such as valine, leucine, and isoleucine biosynthesis. JPYZXZ primarily influences the pentose phosphate pathway; glutathione metabolism; glyoxylate and dicarboxylate metabolism; porphyrin and chlorophyll metabolism; and glycine, serine, and threonine metabolism of patients with GC treated with chemotherapy. CONCLUSIONS: The metabolic characteristics of patients with GC after chemotherapy are mainly various amino acid metabolic defects, especially L-glutamine, L-leucine, L-alloisoleucine, and L-valine. These defects lead to a series of problems, such as decreased tolerance and effectiveness of chemotherapy, increased side effects, decreased immunity, and shortened survival time. In addition, the remarkable upregulation of the gluconolactone level in patients with GC suggests the high proliferative activity of GC cells. Thus, gluconolactone may be used as a potential prognostic and diagnostic evaluation index. Moreover, JPYZXZ can reduce the incidence of ADRs and improve the life quality of patients by the correction of L-glutamine, L-leucine, L-alloisoleucine, and L-valine metabolism deficiency. In addition, gluconolactone metabolism is inhibited by JPYZXZ. Such inhibition may be one of the antitumor mechanisms of JPYZXZ.
OBJECTIVE: This study aimed to find new biomarkers of prognosis and metabolomic therapy for gastric carcinoma (GC) treated with chemotherapy and investigate the metabolic mechanism of the Jianpi Yangzheng Xiaozheng (JPYZXZ) decoction in the treatment of GC. METHODS: First, 36 patients with GC were randomly assigned to the treatment (chemotherapy plus JPYZXZ) and control (chemotherapy alone) groups. The clinical efficacy, side effects, and quality of life of patients in the two groups were evaluated after treatment. Then, the serum samples taken from 16 randomly selected patients (eight treatment cases and eight control cases with no evident pattern characters) and eight healthy volunteers were tested to identify the differential metabolite under the gas chromatography-time-of-fight mass spectrometry platform. The relevant metabolic pathways of differential substances were analyzed using multidimensional statistical analysis. RESULTS: JPYZXZ combined with chemotherapy resulted in a lower risk of leucopenia, thrombocytopenia, and gastrointestinal reaction (P < 0.05). Additionally, patients in the treatment group showed a higher Karnofsky (KPS) scale (P < 0.05). Compared with healthy persons, patients with GC were found to have 26 significant differential metabolites after chemotherapy; these metabolites are mainly involved in 12 metabolic pathways, such as valine, leucine, and isoleucine biosynthesis. JPYZXZ primarily influences the pentose phosphate pathway; glutathione metabolism; glyoxylate and dicarboxylate metabolism; porphyrin and chlorophyll metabolism; and glycine, serine, and threonine metabolism of patients with GC treated with chemotherapy. CONCLUSIONS: The metabolic characteristics of patients with GC after chemotherapy are mainly various amino acid metabolic defects, especially L-glutamine, L-leucine, L-alloisoleucine, and L-valine. These defects lead to a series of problems, such as decreased tolerance and effectiveness of chemotherapy, increased side effects, decreased immunity, and shortened survival time. In addition, the remarkable upregulation of the gluconolactone level in patients with GC suggests the high proliferative activity of GC cells. Thus, gluconolactone may be used as a potential prognostic and diagnostic evaluation index. Moreover, JPYZXZ can reduce the incidence of ADRs and improve the life quality of patients by the correction of L-glutamine, L-leucine, L-alloisoleucine, and L-valine metabolism deficiency. In addition, gluconolactone metabolism is inhibited by JPYZXZ. Such inhibition may be one of the antitumor mechanisms of JPYZXZ.
Authors: Lisa Martin; Pierre Senesse; Ioannis Gioulbasanis; Sami Antoun; Federico Bozzetti; Chris Deans; Florian Strasser; Lene Thoresen; R Thomas Jagoe; Martin Chasen; Kent Lundholm; Ingvar Bosaeus; Kenneth H Fearon; Vickie E Baracos Journal: J Clin Oncol Date: 2014-11-24 Impact factor: 44.544
Authors: Jan Budczies; Carsten Denkert; Berit M Müller; Scarlet F Brockmöller; Frederick Klauschen; Balazs Györffy; Manfred Dietel; Christiane Richter-Ehrenstein; Ulrike Marten; Reza M Salek; Julian L Griffin; Mika Hilvo; Matej Orešič; Gert Wohlgemuth; Oliver Fiehn Journal: BMC Genomics Date: 2012-07-23 Impact factor: 3.969
Authors: Maria D Cao; Santosh Lamichhane; Steinar Lundgren; Anna Bofin; Hans Fjøsne; Guro F Giskeødegård; Tone F Bathen Journal: BMC Cancer Date: 2014-12-12 Impact factor: 4.430
Authors: Pan Pan Wang; Xin Song; Xue Ke Zhao; Meng Xia Wei; She Gan Gao; Fu You Zhou; Xue Na Han; Rui Hua Xu; Ran Wang; Zong Min Fan; Jing Li Ren; Xue Min Li; Xian Zeng Wang; Miao Miao Yang; Jing Feng Hu; Kan Zhong; Ling Ling Lei; Liu Yu Li; Yao Chen; Ya Jie Chen; Jia Jia Ji; Yuan Ze Yang; Jia Li; Li Dong Wang Journal: Front Oncol Date: 2022-01-28 Impact factor: 6.244